Repurposed spinal-cord drug and liver rejuvenation approach target Alzheimer's features

· Science · United States

Two ScienceDaily reports describe experimental approaches that attack Alzheimer's disease through its underlying biology rather than amyloid alone. In one, scientists found that a drug originally developed for spinal cord injuries tackles several key features of Alzheimer's, including DNA damage and inflammation; it has already passed initial human safety testing, which could shorten the path to clinical trials. In the other, USC researchers reported that an experimental drug restored aging liver cells in rats, halving levels of an Alzheimer's-linked protein and bringing bad cholesterol down to youthful levels. Both are preclinical or early-stage results, and the items do not name the compounds, the journals or the magnitude of the cognitive effects, if any. The work fits a broader push toward multi-target and systemic treatments, including links between liver and metabolic health and neurodegeneration.

Why it matters：Alzheimer's drug development has repeatedly failed on amyloid-only approaches; repurposed compounds with existing human safety data and systemic targets such as the liver offer a cheaper, faster route into trials.

Key points

  • The spinal-cord drug has already been tested for initial safety in humans.
  • The USC work halved an Alzheimer's-linked protein in rats.
  • Neither report names the compounds or journals involved.

Sources (original reporting)

More stories from this day